For healthcare professionals. This information does not replace clinical judgement in the individual case; the current summary of product characteristics and the guidelines cited are authoritative.
Medically reviewed: Dr. med. univ. Daniel Pehböck, DESA, 01.11.2026
Tranexamic acid (Antifibrinolytic (lysine analogue)) – indications: Bleeding after trauma – adults, Traumatic brain injury (mild to moderate), Postpartum haemorrhage, Bleeding after trauma – children. Weight-based dosing in mg and ml in the app, with sources.
Indications
- Bleeding after trauma – adults
- Traumatic brain injury (mild to moderate)
- Postpartum haemorrhage
- Bleeding after trauma – children
Complete in the app
Weight-based doses in mg and ml, preparations, contraindications and notes – in the app, also offline.
Used in
Sources and guidelines
- Rossaint R, Afshari A, Bouillon B et al. The European guideline on management of major bleeding and coagulopathy following trauma.
- CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3)
- DGGG/OEGGG/SGGG. Peripartale Blutungen, Diagnostik und Therapie. S2k-Leitlinie, AWMF-Registernummer 015-063, August 2022 (gültig bis 07/2027). Englische Fassung: Geburtshilfe Frauenheilkd, doi 10.1055/a-2073-9615.
- Escobar MF, Nassar AH, Theron G et al. FIGO recommendations on the management of postpartum hemorrhage 2022. Int J Gynaecol Obstet 2022;157 Suppl 1:3–50.
- Djakow J, Turner NM, Skellett S et al. European Resuscitation Council Guidelines 2025 Paediatric Life Support. Resuscitation 2025;215 Suppl 1:110767.
- Resuscitation Council UK. Paediatric advanced life support algorithm.